Emerging Options in Osteoporosis
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.
Overview
Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
HF Management for Patients with Comorbid Conditions
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
Navigating Myasthenia Gravis in Adolescents and Young Adults
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
How Do We Translate Real-World AF Data Into Everyday Clinical Practice?
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?